Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07841977 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis

Name: Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis — clinical trial record (NCT07841977)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorGilead Sciences

Started2026-10

View on ClinicalTrials.gov ↗

Gilead Sciences

107 trials monitored

See 8 trials at risk

The goal of this clinical study is to learn more about the combination of study drugs seladelpar and cilofexor. The study will assess, the safety, tolerability, and effectiveness of the combination drugs versus both seladelpar alone and placebo, in participants with primary biliary cholangitis (PBC). The primary objective of this study is to determine whether the combination of seladelpar + cilofexor leads to greater alkaline phosphatase (ALP) reduction than seladelpar alone and describe the safety and tolerability of seladelpar + cilofexor.

Trial Details

NCT Number	NCT07841977
Lead Sponsor	Gilead Sciences
Conditions	Primary Biliary Cholangitis
Enrollment	132 participants
Start Date	2026-10
Primary Completion	2028-06 (estimated)
Study Completion	2034-06 (estimated)
Updated on ClinicalTrials.gov	2026-09-25